Envveno Medical CORP Form 4 insider transactions

Director Francis Duhay sold 140 shares of enVVeno Medical Corp common stock at an average price of $10.305 per share.

enVVeno Medical Corp Director Francis Duhay sold 140 shares of common stock for $11.5224 per share under a pre-arranged 10b5-1 trading plan.

enVVeno Medical Corp's CEO, Robert Andrew Berman, has voluntarily surrendered 200,000 unvested Restricted Stock Units due to unachieved performance milestones.

enVVeno Medical Corp's Chief Technology Officer, Hamed Alavi, has surrendered 50,000 unvested Restricted Stock Units due to unachieved performance milestones.

enVVeno Medical Corp's SVP & Chief Medical Officer, Marc H. Glickman, is scheduled to surrender 100,000 unvested Restricted Stock Units after failing to meet performance milestones.

enVVeno Medical Corp director Francis Duhay was granted 135,883 stock options with a $0.325 exercise price, vesting quarterly in 2026.

enVVeno Medical Corp director Robert Gray received 135,883 stock options with a $0.325 exercise price, vesting quarterly in 2026.

enVVeno Medical Corp Director Matthew Jenusaitis was granted 135,883 stock options with an exercise price of $0.325, vesting quarterly throughout 2026.

enVVeno Medical Corp director Sanjay Shrivastava was granted 135,883 stock options with a $0.325 exercise price, vesting quarterly in 2026.

enVVeno Medical Corp Director Francis Duhay sold 4,900 shares of common stock for $0.3556 per share on December 11, 2025, as part of a pre-arranged 10b5-1 trading plan.

enVVeno Medical Corp Director Francis Duhay sold 4,900 shares of common stock for a weighted-average price of $0.83 per share under a pre-arranged Rule 10b5-1 trading plan.

Jennifer Bright, CFO of enVVeno Medical Corp, was granted 350,000 stock options on May 19, 2025, according to a Form 4 filing.

Director Francis Duhay of enVVeno Medical Corp purchased 81,433 shares of common stock on December 31, 2024.

Robert Gray, a director at enVVeno Medical Corp, purchased 3,500 shares of common stock at $2.94 per share on December 31, 2024.

Director Sanjay Shrivastava increased his holdings in enVVeno Medical Corp by purchasing 5,400 shares of common stock at $2.90 per share on December 24, 2024.

Director Matthew Jenusaitis of enVVeno Medical Corp purchased 9,620 shares of common stock on the open market at $2.53 per share.

Robert Andrew Berman, CEO of enVVeno Medical Corp, was granted 200,000 stock options on December 18, 2024, which vest quarterly over three years.

Director Francis Duhay acquired 19,752 stock options in enVVeno Medical Corp on December 18, 2024, which vest quarterly throughout 2025.

Robert Gray, a director at enVVeno Medical Corp, acquired 19,752 stock options on December 18, 2024, which vest quarterly throughout 2025.

Hamed Alavi, Chief Technology Officer of enVVeno Medical Corp, was granted 75,000 stock options on December 18, 2024, which vest quarterly over three years.

Director Sanjay Shrivastava acquired 19,752 stock options in Envveno Medical Corp on December 18, 2024.

Marc H. Glickman, SVP & Chief Medical Officer of enVVeno Medical Corp, was granted 75,000 stock options on December 18, 2024.

Matthew Jenusaitis, a director at enVVeno Medical Corp, was granted 19,752 stock options on December 18, 2024.

enVVeno Medical Corp's CEO, Robert Andrew Berman, purchased 12,000 shares of common stock at an average price of $2.55 per share.

Chief Technology Officer of enVVeno Medical Corp, Hamed Alavi, exercised stock options and sold the acquired shares on March 13, 2024.